Translational strategies to schizophrenia from a proteomic perspective

Freedman R., Schizophrenia, N. Engl. J. Med., 2003, 349, 1738–1749 Brown A. S., The environment and susceptibility to schizophrenia, Prog. Neurobiol., 2011, 93, 23–58 Horvath S., Janka Z., Mirnics K., Analyzing schizophrenia by DNA microarrays, Biol. Psychiatry, 2011, 69, 157–162 Johnston-Wilson N. L., Sims C. D., Hofmann J. P., Anderson L., Shore A. D., Torrey E. F., et al., Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium, Mol. Psychiatry, 2000, 5, 142–149 Martins-de-Souza D., Guest P. C., Rahmoune H., Bahn S., Proteomic approaches to unravel the complexity of schizophrenia, Expert Rev. Proteomics, 2012, 9, 97–108 Martins-De-Souza D., Dias-Neto E., Schmitt A., Falkai P., Gormanns P., Maccarrone G., et al., Proteome analysis of schizophrenia brain tissue, World J. Biol. Psychiatry, 2010, 11, 110–120 Krishnamurthy D., Harris L. W., Levin Y., Koutroukides T. A., Rahmoune H., Pietsch S., et al., Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects, World J. Biol. Psychiatry, 2012, [Epub ahead of print] Huang J. T., Leweke F. M., Oxley D., Wang L., Harris N., Koethe D., et al., Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis, PLoS Med., 2006, 3, e428 Martins-De-Souza D., Wobrock T., Zerr I., Schmitt A., Gawinecka J., Schneider-Axmann T., et al., Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls, World J. Biol. Psychiatry, 2010, 11, 719–728 Prabakaran S., Wengenroth M., Lockstone H. E., Lilley K., Leweke F. M., Bahn S., 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia, J. Proteome Res., 2007, 6, 141–149 Herberth M., Koethe D., Cheng T. M., Krzyszton N. D., Schoeffmann S., Guest P. C., et al., Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients, Mol. Psychiatry, 2011, 16, 848–859 Wang L., Lockstone H. E., Guest P. C., Levin Y., Palotás A., Pietsch S., et al., Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia, J. Proteome Res., 2010, 9, 521–527 Guest P. C., Wang L., Harris L. W., Burling K., Levin Y., Ernst A., et al., Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients, Mol. Psychiatry, 2010, 15, 118–119 Levin Y., Wang L., Schwarz E., Koethe D., Leweke F. M., Bahn S., Global proteomic profiling reveals altered proteomic signature in schizophrenia serum, Mol. Psychiatry, 2010, 15, 1088–1100 Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J. P., Guest P. C., et al., Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia, Biomark. Insights, 2010, 5, 39–47 Schwarz E., Guest P. C., Rahmoune H., Harris L. W., Wang L., Leweke F. M., et al., Identification of a biological signature for schizophrenia in serum, Mol. Psychiatry, 2012, 17, 494–502 Bahn S., Noll R., Barnes A., Schwarz E., Guest P. C., Challenges of introducing new biomarker products for neuropsychiatric disorders into the market, Int. Rev. Neurobiol., 2011, 101, 299–327 Ji B., La Y., Gao L., Zhu H., Tian N., Zhang M., et al., A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications, J. Proteome Res., 2009, 8, 3633–3641 Chan M. K., Tsang T. M., Harris L. W., Guest P. C., Holmes E., Bahn S., Evidence for disease and antipsychotic medication effects in postmortem brain from schizophrenia patients, Mol. Psychiatry, 2011, 16, 1189–1202 Ahmed E. U., Ahmed S., Ukai W., Matsumoto I., Kemp A., McGregor I. S., et al., Antipsychotic induced alteration of growth and proteome of rat neural stem cells, Neurochem. Res., 2012, 37, 1649–1659 Gottschalk M. G., Sarnyai Z., Guest P. C., Harris L. W., Bahn, S., Translational neuropsychiatry of genetic and neurodevelopmental animal models of schizophrenia, Rev. Psiquiatr. Clin., 2012, in press Yanagi M., Southcott S., Lister J., Tamminga C. A., Animal models of schizophrenia emphasizing construct validity, Prog. Mol. Biol. Transl. Sci., 2012, 105, 411–444 Martins-de-Souza D., Alsaif M., Ernst A., Harris L. W., Aerts N., Lenaerts I., et al., The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia, BMC Res. Notes, 2012, 5, 146 Paulson L., Martin P., Nilsson C. L., Ljung E., Westman-Brinkmalm A., Blennow K., et al., Comparative proteome analysis of thalamus in MK-801-treated rats, Proteomics, 2004, 4, 819–825 Martins-de-Souza D., Lebar M., Turck C. W., Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia, Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261, 217–228 Steiner J., Sarnyai Z., Westphal S., Gos T., Bernstein H. G., Bogerts B., et al., Protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes, Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261, 477–482 Bernstein H. G., Steiner J., Bogerts B., Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy, Expert Rev. Neurother., 2009, 9, 1059–1071 Martins-de-Souza D., Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia, J. Psychiatr. Res., 2010, 44, 149–156